NEW YORK (GenomeWeb News) – The National Cancer Institute has extended an existing agreement with synthetic genomics company GeneArt to produce genes for the NCI’s Mammalian Gene Collection, the company said today.
GeneArt said that it stands to gain an additional $800,000 from the expanded contract, bringing the total value of the agreement to $2.7 million in 2008.
The company said it netted $3.5 million in 2007 from the NCI contract, which was renewed earlier this year.
GeneArt said that the genes it has produced to date for the MGC are made of complex repeat motifs, are large, and are primarily rare transcripts. The company said it has recently advanced its synthesis processes and developed new production techniques to in order to produce the complex genes efficiently.